Arbutus Biopharma Corporation (0SGC.L)
| Previous Close | 2.7250 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 1,411 |
| Market Cap | N/A |
| Beta (5Y Monthly) | 2.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7050 |
| Earnings Date | May 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireArbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 2024. The schedule for the press release and conference call/webcast are as follows: •Q1 2024 Press Relea
- GlobeNewswire
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today issued the following statement regarding the claim construction ruling of the U.S. District Court for the District of Delaware in the lawsuit brought by Arbutus and its licensee Genevant Sciences (Plaintiffs) against Mod
Simply Wall St.Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
